An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis

NCT ID: NCT01337388

Last Updated: 2016-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

197 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-08-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will assess the efficacy and safety of RoActemra/Actemra (Tocilizumab) in smoking versus non-smoking patients with rheumatoid arthritis. Data from patients treated in routine clinical practice with intravenous RoActemra/Actemra will be collected for 12 months each.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \> 18 years of age
* Rheumatoid arthritis, defined as fulfilling at least 4 of 7 American College of Rheumatology (ACR) criteria
* Treatment with RoActemra/Actemra

Exclusion Criteria

* Participation in interventional clinical studies
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ålesund, , Norway

Site Status

Bergen, , Norway

Site Status

Drammen, , Norway

Site Status

Gjettum, , Norway

Site Status

Kristiansand, , Norway

Site Status

Levanger, , Norway

Site Status

Lillehammer, , Norway

Site Status

Skien, , Norway

Site Status

Trondheim, , Norway

Site Status

Eskilstuna, , Sweden

Site Status

Falun, , Sweden

Site Status

Farsta, , Sweden

Site Status

Gothenburg, , Sweden

Site Status

Kalmar, , Sweden

Site Status

Karlstad, , Sweden

Site Status

Kristianstad, , Sweden

Site Status

Linköping, , Sweden

Site Status

Luleå, , Sweden

Site Status

Malmo, , Sweden

Site Status

Oskarström, , Sweden

Site Status

Örebro, , Sweden

Site Status

Östersund, , Sweden

Site Status

Simrishamn, , Sweden

Site Status

Skövde, , Sweden

Site Status

Stockholm, , Sweden

Site Status

Stockholm, , Sweden

Site Status

Uddevalla, , Sweden

Site Status

Uppsala, , Sweden

Site Status

Västerås, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Norway Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ML25492

Identifier Type: -

Identifier Source: org_study_id